Prevalence of cardiometabolic risk factors and selected cardiovascular diseases in hypertensive and normotensive participants in the adult Polish population: The WOBASZ II study.
Adult
Aged
Aged, 80 and over
Blood Pressure
/ physiology
Cardiovascular Diseases
/ epidemiology
Comorbidity
Female
Follow-Up Studies
Humans
Hypertension
/ epidemiology
Male
Metabolic Syndrome
/ epidemiology
Middle Aged
Poland
/ epidemiology
Prevalence
Retrospective Studies
Risk Assessment
/ methods
Risk Factors
Young Adult
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
10 Jul 2020
10 Jul 2020
Historique:
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
23
7
2020
Statut:
ppublish
Résumé
Hypertension is one of the most important causes of cardiovascular disease (CVD) incidence and mortality. The aim of the study was to assess the prevalence of metabolic syndrome and its individual components i.e., diabetes, obesity, elevated triglycerides (TG), low HDL (high-density lipoprotein) cholesterol, as well as selected manifestations of CVD i.e., atrial fibrillation (AF), peripheral artery disease (PAD), coronary artery disease (CAD), myocardial infarction (MI), and stroke in persons with and without hypertension in the Polish population.The analysis included participants of Polish multicentre WOBASZ II Study i.e., 6163 persons aged 19 and above. The Mantel Haenszel anlysis and multidimensional logistic regression model were used to assess the relations between the prevalence of metabolic syndrome and its individual components as well as selected manifestations of CVD with hypertension.Compared to normotensives, metabolic syndrome was over 5 times more prevalent in participants with hypertension (OR = 5.35, 95% CI:4.71-6.09). Components of the metabolic syndrome and selected manifestations of CVD were more prevalent in participants with hypertension compared to normotensives. The Mantel-Haenszel odds ratios (95% confidence intervals) were as follows: obesity counted as BMI > 30 kg/m OR = 2.58 (2.26-2.96), raised triglycerides OR = 2.34 (2.07-2.64), reduced HDL-C OR = 1.81 (1.59-2.06), metabolic syndrome OR = 5.35 (4.71-6.09), diabetes OR = 2.54 (1.98-3.26), AF OR = 1.47 (1.09-2.00), PAD OR = 1.51 (1.14-1.99), CAD OR = 1.94 (1.52-2.49), MI OR = 1.89 (1.32-2.70), hospitalization due to HF OR = 2.02 (1.43-2.87), hospitalization due to exacerbation of CAD OR = 2.13 (1.58-2.86), hospitalization due to revascularization OR = 2.38 (1.49-3.80), hospitalization due to stroke OR = 1.72 (1.1-2.68).Compared to normotensive participants, persons with hypertension had higher prevalence of diabetes, obesity, MS, PAD, CAD, stroke, MI and AF, and more frequent need for hospitalization due to HF, exacerbation of CAD and for coronary revascularization.
Identifiants
pubmed: 32664148
doi: 10.1097/MD.0000000000021149
pii: 00005792-202007100-00098
pmc: PMC7360309
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21149Références
Eur J Epidemiol. 1995 Apr;11(2):199-205
pubmed: 7672076
Can J Cardiol. 1988 Jul;4 Suppl A:5A-10A
pubmed: 3179802
Am J Hypertens. 2000 Jan;13(1 Pt 2):3S-10S
pubmed: 10678282
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
BMJ Open. 2013 Aug 30;3(8):e003423
pubmed: 23996822
J Hypertens. 2013 Jul;31(7):1281-357
pubmed: 23817082
Scand J Public Health. 2015 Mar;43(2):212-9
pubmed: 25592449
Arch Med Sci. 2018 Aug;14(5):951-961
pubmed: 30154875
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752
Pol Arch Med Wewn. 2016 Aug 18;126(9):662-671
pubmed: 27535012
Stroke. 2000 Jan;31(1):2-8
pubmed: 10625707
Kardiol Pol. 2015;73(10):958-61
pubmed: 26521843
BMC Public Health. 2017 Jul 13;18(1):15
pubmed: 28705231
J Hypertens. 2000 Aug;18(8):999-1006
pubmed: 10953989
Kardiol Pol. 2015;73(8):676-700
pubmed: 26304155
Cardiol Res Pract. 2012;2012:925046
pubmed: 22242212
Kardiol Pol. 2016;74(7):681-90
pubmed: 26620680
J Hum Hypertens. 2009 May;23(5):316-24
pubmed: 19005476
Pol Arch Med Wewn. 2016 Jul 19;126(9):642-652
pubmed: 27452484